221 related articles for article (PubMed ID: 34918004)
1. LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease.
Yazd HS; Bazargani SF; Vanbeek CA; King-Morris K; Heldermon C; Segal MS; Clapp WL; Garrett TJ
J Mass Spectrom Adv Clin Lab; 2021 Nov; 22():71-78. PubMed ID: 34918004
[TBL] [Abstract][Full Text] [Related]
2. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
[TBL] [Abstract][Full Text] [Related]
3. Analysis of globotriaosylceramide (Gb
Toupin A; Lavoie P; Arthus MF; Abaoui M; Boutin M; Fortier C; Ménard C; Bichet DG; Auray-Blais C
Anal Chim Acta; 2018 Jul; 1015():35-49. PubMed ID: 29530250
[TBL] [Abstract][Full Text] [Related]
4. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
5. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
Shiga T; Tsukimura T; Kubota T; Togawa T; Sakuraba H
Intern Med; 2024 Jun; 63(11):1531-1537. PubMed ID: 37866916
[TBL] [Abstract][Full Text] [Related]
6. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
[TBL] [Abstract][Full Text] [Related]
7. Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients.
Boutin M; Lavoie P; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.23.1-17.23.9. PubMed ID: 27367163
[TBL] [Abstract][Full Text] [Related]
8. Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease.
Taguchi A; Ishii S; Mikame M; Maruyama H
Mol Genet Metab Rep; 2023 Mar; 34():100952. PubMed ID: 36624895
[TBL] [Abstract][Full Text] [Related]
9. Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
Tsukimura T; Shiga T; Saito K; Ogawa Y; Sakuraba H; Togawa T
Mol Genet Metab Rep; 2021 Sep; 28():100773. PubMed ID: 34136356
[TBL] [Abstract][Full Text] [Related]
10. Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease.
Ishii S; Taguchi A; Okino N; Ito M; Maruyama H
J Biol Chem; 2020 Apr; 295(17):5577-5587. PubMed ID: 32179651
[TBL] [Abstract][Full Text] [Related]
11. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
[TBL] [Abstract][Full Text] [Related]
12. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
13. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.
Lavoie P; Boutin M; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162
[TBL] [Abstract][Full Text] [Related]
14. Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease.
Shiga T; Tsukimura T; Namai Y; Togawa T; Sakuraba H
Mol Genet Metab Rep; 2021 Dec; 29():100804. PubMed ID: 34631425
[TBL] [Abstract][Full Text] [Related]
15. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.
Tsukimura T; Tayama Y; Shiga T; Hirai K; Togawa T; Sakuraba H
Mol Genet Metab Rep; 2020 Dec; 25():100650. PubMed ID: 33072516
[TBL] [Abstract][Full Text] [Related]
16. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Globotriaosylceramide (Gb
Boutin M; Maranda B; Waters PJ
Curr Protoc; 2024 Jun; 4(6):e1087. PubMed ID: 38896100
[TBL] [Abstract][Full Text] [Related]
18. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
19. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers.
Dupont FO; Gagnon R; Boutin M; Auray-Blais C
Curr Med Chem; 2013; 20(2):280-8. PubMed ID: 23092136
[TBL] [Abstract][Full Text] [Related]
20. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]